sometim best defens offens
fog start lift today strong switch data partial address
franchis durat question believ investor still look
bd initi revamp growth stori name could see
sentiment start shift favor stock go forward
demonstr non-inferior soliri two pnh studi nave switch
numer trend favor clear clinic efficaci combin
substanti improv dose regimen infus per
year versu soliri offer compel argument switch
patient believ major patient like convert
biosimilar becom avail current model
convers year across territori
eu patent overhang may overblown discuss
manag clarifi item relat pend soliri patent
on-going interact process european patent offic epo
decis issuanc expect certain could
offer protect extend new patent could cover
claim contempl new soliri patent issu
us composit matter pharmaceut formul method
treat pnh potenti challeng new patent could take year
resolv nine month patent grant epo check
opposit notic file initi review opposit take
month appeal process could take addit year
valuat reiter outperform rate tp updat
model line actual new manag guidanc take
non-gaap ep risk thesi includ
commerci regulatori clinic headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
alexion biotechnolog compani focus research
develop commerci therapeut rare diseas
alexion drug soliri use treat patient complement
mediat disord product includ strensiq
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
establish superior efficaci soliri pnh
trial posit nmo data increas pipelin valu
fail establish non-inferior efficaci soliri failur
nmo decreas pipelin valu
 close
million except ep
incom tax non-gaap
charl martineau univers toronto compani mention price
